In May 2024, Knight entered into an agreement with Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary of Ironshore Therapeutics, Inc. (now part of Collegium Pharmaceutical, Inc.; ...

IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Health Canada ...

Health Canada's approval is based on data from the Phase 3 clinical trial ConquerRSV, a global study conducted in approximately 37,000 adults aged 60 years and older in 22 countries. No serious safety ...

ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Health Canada ...

Q3 2024 Earnings Call Transcript November 8, 2024 Operator: Good morning and welcome to Ocugen’s Third Quarter 2024 Financial ...

More collaborative initiatives are taking place among regulatory agencies, health technology assessment (HTA) bodies and ...

Ocugen (NASDAQ: OCGN) Q3 2024 Earnings Call Nov 08, 2024, 8:30 a.m. ET Good morning and welcome to Ocugen's third quarter 2024 financial results and business update. [Operator instructions] I will now ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, and Dr. Marjorie Green, senior vice president and ...

Sotatercept is the first activin signaling inhibitor therapy for PAH in Canada , a new class of therapy that works by improving the balance between pro-proliferative and anti-proliferative signaling ...

Q3 2024 Earnings Call Transcript November 7, 2024 Operator: Thank you for standing by. My name is Kris and I will be your ...

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti ...